

Abstract

26

27 Deep brain stimulation (DBS) targeting the lateral habenula (LHb) is a promising
28 therapy for treatment-resistant depression (TRD) but its clinical effect has been
29 variable, which can be improved by adaptive DBS (aDBS) guided by a neural
30 biomarker of depression symptoms. A clinically-viable neural biomarker is desired to
31 classify depression symptom states, track both slow and fast symptom variations
32 during the treatment, respond to DBS parameter alterations, and be neurobiologically
33 interpretable, which is currently lacking. Here, we conducted a study on one TRD
34 patient who achieved remission following a 41-week LHb DBS treatment, during
35 which we assessed slow symptom variations using weekly clinical ratings and fast
36 variations using daily self-reports. We recorded daily LHb local field potentials (LFP)
37 concurrently with the reports during the entire treatment process. We then used
38 machine learning methods to identify a personalized depression neural biomarker
39 from spectral and temporal LFP features. The identified neural biomarker classified
40 high and low depression symptom severity states with a cross-validated accuracy of
41 0.97, with the most contributing spectral and temporal feature being LFP beta band
42 power and Hurst exponent, respectively. It further simultaneously tracked both
43 weekly (slow) and daily (fast) depression symptom variation dynamics, achieving test
44 data explained variance of 0.74 and 0.63, respectively. It also responded to DBS
45 frequency alterations. Finally, it can be neurobiologically interpreted as indicating
46 changes in LHb excitatory and inhibitory balance during DBS treatment. Together,
47 our results hold promise to identify clinically-viable neural biomarkers to facilitate
48 future aDBS for treating TRD.

49 1. Introduction

50 Major depressive disorder (MDD) is one of the most common neuropsychiatric
51 disorders, affecting over 300 million individuals worldwide [1]. Approximately 30%
52 of MDD patients are treatment-resistant, meaning they do not respond adequately to
53 at least two antidepressant trials [2]. Deep brain stimulation (DBS) is a neurosurgical
54 procedure that allows targeted circuit-based neuromodulation [3]. It has emerged as a
55 promising treatment option for patients with treatment-resistant depression (TRD) [4–
56 6], as shown by open-label studies targeting various brain structures involved in the
57 brain’s “reward” system that mediates positive motivations. Such targets include the
58 subcallosal cingulate cortex (SCC) [7], the ventral capsule/ventral striatum (VC/VS)
59 [8], the medial forebrain bundle (MFB) [9], and the bed nucleus of the stria terminalis
60 (BNST) [10]. However, several recent double-blinded clinical trials have shown that
61 the effects of DBS targeting these brain structures are inconsistent across patients
62 [11–15]. As a potential improvement over DBS, adaptive DBS (aDBS) optimizes
63 DBS parameters in real-time by using neural signals as feedback for enhancing
64 clinical efficacy [16]. A recent study implements aDBS targeting VC/VS in a TRD
65 patient by triggering stimulation only when the local field potential (LFP) signal
66 pattern indicates worsening of depression symptoms, achieving rapid alleviation of
67 depression symptoms [17].

68 The lateral habenula (LHb) is a hub structure that plays a central role in the brain’s
69 “anti-reward” system that mediates negative motivations [18–20]. Animal studies
70 have systematically shown that the local bursting firing patterns in LHb are closely
71 related to depression-like behaviors and that neuromodulation of LHb has significant

72 antidepressant effects [21–23]. Several clinical studies have reported single-patient
73 depression symptom alleviation following LHb DBS since 2010 [24–27]. On the
74 other hand, two recent clinical studies on seven or six patients has shown more
75 variable effects of LHb DBS across patients [28,29]. Similar to other DBS targets,
76 aDBS for LHb also provides a promising path towards improved and more consistent
77 treatment effects across TRD patients.

78 A critical and fundamental requirement for developing LHb aDBS is the
79 identification of an LHb neural biomarker of depression symptoms during the DBS
80 treatment to provide the necessary feedback signal [30,31]. A population-level SCC
81 LFP spectral power biomarker has been identified for tracking depression symptom
82 recovery with SCC DBS in five TRD patients [32]. Personalized amygdala and BNST
83 LFP gamma power biomarkers have been identified for optimizing VC/VS DBS [33].
84 For LHb DBS, LFP signals have been recorded before the DBS treatment starts but
85 not during the multi-month-long treatment process [28,29,34] and several studies
86 have found statistical correlations between pre-treatment LHb LFP spectral features
87 and after-treatment depression symptom ratings [28,29,34]. However, it is unknown
88 whether the identified LFP features can classify depression symptom severity states
89 or track the temporal dynamics of depression symptom variations during the DBS
90 treatment process. Therefore, a useful neural biomarker for realizing LHb aDBS is
91 still lacking.

92 A clinically-viable neural biomarker is desired to be able to track both the slow
93 and fast temporal dynamics of depression symptom variations during DBS. This is
94 because both natural and DBS-induced depression symptom changes can vary at
95 different time scales, with both slow-changing dynamics over months or weeks [35–

96 39] and fast-changing dynamics over hours or days [9,40–43]. Existing neural
97 biomarker studies have focused on tracking the temporal dynamics of either slow or
98 fast symptom variations. The aforementioned SCC neural biomarker for SCC DBS
99 tracks the temporal dynamics of the weekly symptom variations over 24 weeks [32].
100 The aforementioned amygdala and BNST neural biomarkers for VC/VS DBS track
101 the faster temporal dynamics of symptom variations within several days [17,33].
102 Several other studies have also identified resting-state (without DBS) neural
103 biomarkers of relatively fast depression symptom variations within several days using
104 multisite intracranial electroencephalography (iEEG) [44–46]. However, to date,
105 identifying a neural biomarker that can simultaneously track the temporal dynamics
106 of both slow and fast depression symptom variations, in particular during LHb DBS
107 treatment, remains elusive.

108 Moreover, the neural biomarker needs to reflect the dose effect of different DBS
109 parameters for optimizing stimulation parameters in aDBS. Since the DBS
110 mechanism for treating TRD is largely unknown [47], only few studies have
111 experimentally explored the dose effect of different DBS amplitudes on human neural
112 signals [17,32,33]. On the other hand, DBS frequency also has been shown to play a
113 key role in altering TRD symptoms [4–6,48]. However, how different LHb DBS
114 parameters, especially stimulation frequencies, alter neural signals or neural
115 biomarkers in TRD patients remains unknown.

116 Finally, the neural biomarker should possess a certain level of neurobiological
117 interpretability. A critical neurobiological property that has been implicated in the
118 pathophysiology of MDD [21–23] is the excitatory/inhibitory (E/I) balance of LHb
119 activity. E/I balance refers to the equilibrium between synaptic excitation and

120 inhibition received by neurons [49]. LHb has excitatory and inhibitory connections
121 with a wide range of brain regions involved in the affect, reward, and cognition
122 dimensions of MDD symptom, such as the dorsal raphe nucleus, nucleus accumbens,
123 hippocampus, medial prefrontal cortex, etc [50]. Excessive excitation of LHb has
124 been implicated in the pathology of MDD [21–23]. By contrast, electrical stimulation
125 of LHb in animal depression models has been shown to inhibit overly-excited local
126 neural activity, thus modulating the dopaminergic and serotonergic activity and
127 generate complex excitatory and inhibitory effects over a large network that may have
128 led to depression-like behavior alleviation [51,52]. Furthermore, a prior study has
129 found a correlation between pre-treatment LHb E/I balance with depression
130 symptoms in DBS patients [34]. However, how LHb E/I balance changes during
131 human patient DBS treatment and whether there exists a neural biomarker that can
132 track such changes has not been investigated.

133 Here, to close the above gaps, we conducted LHb DBS on one TRD patient where
134 we evaluated the patient’s symptoms and concurrently collected daily LHb LFP
135 signals during the entire 41-week long treatment process (Figure 1). With this unique
136 longitudinal dataset and by using machine learning techniques, we identified a
137 clinically-viable neural biomarker from spectral and temporal LHb features, where
138 the most contributing spectral and temporal features are the β (12-30 Hz) band power
139 and Hurst exponent, respectively. Our identified neural biomarker (1) accurately
140 classified high and low depression symptom severity states; (2) significantly tracked
141 the temporal dynamics of weekly (slower) and daily (faster) depression symptom
142 variations during the DBS treatment; (3) reflected the depression symptom changes




Figure 1. Study framework. During the Lhb DBS treatment of one TRD patient, we used weekly clinical ratings and daily self-reports to evaluate the symptom variations, where we simultaneously collected daily LFP signals from Lhb. Using machine learning models, we identified a neural biomarker that classified high and low depression symptom states during the DBS treatment. Using data not used in neural biomarker identification, we evaluated and interpreted the neural biomarker in terms of 1) simultaneously tracking the temporal dynamics of weekly slow and daily fast variations of depression symptoms; 2) reflecting symptom changes when DBS frequencies were altered; 3) indicating changes in Lhb E/I balance.

143 in response to DBS frequency alterations. Finally, the neural biomarker can be
 144 interpreted as an indicator of the changes in Lhb E/I balance during the DBS
 145 treatment. Together, our results have implications for identifying clinically-viable
 146 neural biomarkers to facilitate future Lhb aDBS developments for treating TRD.

147 **2. Materials and Methods**

148 **2.1 Participant**

149 This study included a male TRD patient aged 36-40 years old (see Note S1 for detailed
 150 patient medical information) participating in a clinical trial of Lhb DBS treatment
 151 starting in October 2021. The patient provided informed consent for participation in

152 the clinical trial. This study received approval from the Ethics Committee of Zhejiang
153 University School of Medicine Second Affiliated Hospital (protocol number
154 20210218). It was registered at www.clinicaltrials.gov (IR2021001074), where
155 detailed information regarding the inclusion and exclusion criteria can be accessed.

156 At the beginning of the clinical trial, two independent psychiatrists evaluated the
157 patient's psychotic symptoms using the 17-item Hamilton Depression Rating Scale
158 (HAMD), the Montgomery Asberg Depression Scale (MADRS), and the Hamilton
159 Anxiety Rating Scale (HAMA) as baseline assessments. In addition to the psychiatric
160 assessments, the patient underwent a comprehensive physical examination, various
161 mental scale assessments, and a magnetic resonance imaging (MRI) examination. We
162 carefully ensured that other psychiatric diagnoses outlined in the Diagnostic and
163 Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) were excluded.

164 **2.2 Surgical procedure**

165 A standard DBS implantation procedure was employed. Bilateral quadripolar
166 electrodes (1200-40, SceneRay, Suzhou, China) were surgically implanted in the LHb
167 under local anesthesia (Figure 2A). The DBS electrodes had a diameter of 1.27 mm
168 and a lead length of 400 mm. Each electrode's four contacts measured 1.5 mm in
169 length with a spacing of 0.5 mm. The LHb targeting was guided by preoperative MRI
170 sequences. After confirming the absence of stimulation side effects through
171 intraoperative testing, an implantable pulse generator (SR1101, SceneRay) was
172 placed under general anesthesia. The DBS device was also capable of recording and
173 wireless transmitting LFP signals (Figure 2B).




Figure 2. Experiment design. (A) MRI visualization showing the DBS lead placement within the patient's LHB. The shaded blue area indicates the volume of tissue activated by the DBS. (B) Temporal dynamics of example epochs of LFP signals after preprocessing. (C) Lhb DBS Treatment Timeline. The entire treatment process consisted of six stages. LFP signal collection began after the activation of 1 Hz stimulation. (D) Longitudinal data collection over time. Data were collected using two different time scales: 1) daily self-reports and 30-min LFP signals recorded around the self-reports; 2) weekly clinical ratings.

174 2.3 Fiber tracking of LHB

175 We used diffusion tensor images from the magnetic resonance imaging (MRI)
 176 examination to conduct fiber tracking of LHB with a standard procedure reported in
 177 a previous study [53]. First, we manually created the LHB as the region of interest
 178 (ROI) in standard Montreal Neurological Institute 152 (MNI152) space. The ROI in
 179 MNI152 standard space was then registered to the diffusion space of our patient for

180 tractography. To ensure the exclusion of non-brain tissue, we employed the 'bet2'
181 function, and the cerebrospinal fluid mask was used as an exclusion mask. We further
182 performed the probabilistic tractography processing using tools from the FSL
183 Diffusion Toolbox. The LHb ROI was used as the seed mask to generate whole-brain
184 distribution maps using FSL's probtrackX tool. We performed 5000 streamline
185 samples per voxel with distance normalization to ensure comprehensive coverage.
186 Subsequently, the resulting fiber distribution maps were non-linearly registered back
187 to the MNI152 standard space. To eliminate artifactual connections and noise, a
188 threshold value of 1% was implemented.

189 **2.4 DBS treatment process and symptom evaluations**

190 During the bilateral DBS treatment process, we made multiple adjustments to the
191 stimulation parameters to achieve the best therapeutic effect. We divided the treatment
192 process into six stages based on the alterations of stimulation parameters (Figure 2C):
193 1) the “Preop” stage, the time before DBS implantation; 2) the “Off-1” stage, patient
194 recovery with DBS turned off; 3) the “1 Hz” stage, activation of 1 Hz stimulation; 4)
195 the “Off-2” stage, DBS turned off because of unnoticed power off; 5) the “20 Hz”
196 stage, re-activation of 20 Hz stimulation; 6) the “130 Hz” stage, activation of 130 Hz
197 stimulation. More details can be found in Note S2. The entire duration of DBS
198 treatment spanned 41 weeks (starting from DBS implantation).

199 The efficacy of DBS treatment was evaluated from two perspectives: clinician
200 evaluation and self evaluation (Figure 2D). For clinician evaluation, a psychologist
201 blinded to the current stimulation parameters and their adjustments evaluated the
202 patient’s depression and anxiety symptoms on a weekly basis using standardized

203 rating scales (HAMD, MADRS, HAMA). Response is defined as a 50% or greater
204 improvement on the HAMD score from the pre-treatment baseline. Remission is
205 defined as achieving a HAMD score of 7 or less. The psychologist also evaluated the
206 patient's emotional blunting and cognitive functioning during the treatment. For every
207 four to six months, the psychologist utilized the Oxford Depression Questionnaire
208 (ODQ), a self-report tool to assess emotional blunting, along with two cognitive
209 assessment tools (MATRICS Consensus Cognitive Battery (MCCB) and THINC-
210 integrated tool (THINC-it)) to evaluate the patient's cognitive abilities. For self
211 evaluation, the patient used the Visual Analogue Scale (VAS) for depression (VAS-D)
212 and anxiety (VAS-A) to self-report the symptom severity. Self-reported VASA and
213 VAS-D had been used to assess the rapid effects of antidepressants [54]. To facilitate
214 daily data collection, we established an online questionnaire system where the patient
215 could conveniently complete the self-reports via the smartphone or computer.

216 **2.5 LFP signal recording, signal processing, and feature** 217 **extraction**

218 After activating the 1 Hz stimulation, we collected daily LFP signals (30 minutes per
219 day) concurrent with daily self-reported VAS-D and VAS-A (Figure 2D, details in
220 section 2.4). LFP signals were recorded at a sampling rate of 1000 Hz. Notably,
221 stimulation was deactivated during the signal acquisition process. We reconstructed
222 the electrode positions using MRI and selected two contacts in the left hemisphere for
223 bipolar recording of a single LFP channel. The patient was instructed to attempt daily
224 LFP recording and VAS-D/VAS-A reporting. Throughout the entire 41-week (287-
225 day) treatment, the patient was able to activate LFP recording and report VAS-D and

226 VAS-A on 122 days distributed across 26 weeks. Therefore, the subsequent analyses
227 focused on the LFP signals, VAS-D, and VAS-A scores recorded from these 122 days,
228 and the HAMD, MADRS, and HAMA scores recorded for the 26 weeks.

229 Custom MATLAB scripts (MathWorks Inc., Natick, MA, USA) were used to
230 preprocess the LFP signals. The LFP signals were first band-pass filtered from 1 to
231 30 Hz using a Butterworth filter of order 12 to avoid the noise observed in higher
232 frequency bands. Then, we divided the daily 30-minute LFP signals into 10-second
233 epochs with a 50% overlap. Next, we used a standard procedure (details in Note S4)
234 to remove bad epochs from daily LFP signals (example temporal traces of
235 preprocessed LFP epochs were shown in Figure 2B).

236 For each remaining LFP epoch, we computed its spectral domain (SD) and
237 temporal domain (TD) features. SD features included PSD of the four bands (δ (delta,
238 1-4 Hz), θ (theta, 4-8 Hz), α (alpha, 8-12 Hz), and β (beta, 12-30 Hz)) and phase-
239 amplitude coupling (PAC) for six specific pairs of coupling. TD features included
240 fourteen temporal domain features used in previous study [55], e.g., Hjorth mobility,
241 Higuchi fractal dimension, Kurtosis, peak-to-peak amplitude, Hurst exponent, etc.
242 These features capture the temporal properties of LFP from probabilistic distribution
243 and information theory perspectives and have been widely used in brain signal
244 analyses [56,57]. As a result, we obtained 24 features, comprising 10 SD features and
245 14 TD features for each LFP epoch. Details of these 24 features are included in Table
246 S1 and Note S3. Finally, we averaged each feature across LFP epochs within the same
247 day and obtained a single averaged 24-dimensional LFP feature vector. Our
248 subsequent analyses were based on the daily LFP features as computed above.

249 **2.6 Correlational analyses between LFP features and symptoms**

250 We conducted Spearman’s rank correlation analyses between LFP features and
251 symptoms. For each day, we correlated each daily LFP feature with the daily VAS-D
252 and VAS-A. For each week, we computed the average of LFP features across the days
253 that belonged to this week, resulting in weekly LFP features; we then correlated each
254 weekly LFP feature with the weekly clinical evaluation scales HAMD, HAMA, and
255 MADRS. Bonferroni correction was used to adjust for multiple comparisons.

256 **2.7 Identification of neural biomarker**

257 Next, we used a data-driven method to identify an LHb neural biomarker of
258 depression symptoms, where we built a machine learning model to use LFP features
259 to classify high and low depression symptom states.

260 First, we defined the high and low depression symptom states of the patient by k-
261 means clustering the weekly depression scales HAMD and MADRS similar to prior
262 work [17]. Among the total 26 weeks (122 days) of LFP data, 7 weeks (29 days) of
263 LFP data belonged to the low depression symptom state (labeled 0), 4 weeks (22 days)
264 of LFP data belonged to the high depression symptom state (labeled 1). The remaining
265 15 weeks (71 days) belonging to the transition symptom state were unlabeled and
266 used as test data for subsequent biomarker tracking evaluation (see next section).

267 Second, based on the labeled data, we built a machine learning model to use the
268 LFP features to classify high and low depression symptom states. We constructed six
269 machine learning models: logistic regression (LR), multilayer perceptron, adaptive
270 boosting, support vector machine, random forest, and linear discriminant analysis. We

271 trained and tested these models using 5-fold cross-validations that were repeated 200
272 times, where we computed the averaged cross-validated classification accuracy,
273 specificity, sensitivity, F1 score, and Receiver Operating Characteristic (ROC) Area
274 Under the Curve (AUC) score as the performance metrics. The model with the highest
275 accuracy was selected for further analyses.

276 Third, the chosen model was retrained with all labeled data, leading to a “neural
277 biomarker model”. This model takes the LFP feature as input and outputs the decision
278 variable as the neural biomarker value (e.g., in the LR model, the decision variable
279 was computed from the decision probability via the inverse sigmoid function). This
280 allows us to compute a neural biomarker value for any given LFP feature. Higher
281 neural biomarker values indicate more severe depression symptoms.

282 In essence, our identified neural biomarker aggregates spectral and temporal
283 domain features from the LHb LFP signal to classify high and low depression states
284 during DBS treatment.

285 **2.8 Evaluation of the neural biomarker**

286 We evaluated the neural biomarker in terms of (1) tracking the temporal dynamics of
287 weekly symptom variations; (2) tracking the dynamics of daily symptom variations;
288 (3) reflecting changes in symptom variations induced by DBS frequency alterations.

289 First, we investigated tracking the temporal dynamics of weekly depression and
290 anxiety symptom scales that were not used in neural biomarker identification. We
291 took the daily LFP features as inputs to the neural biomarker model and computed the
292 output daily neural biomarkers. We then averaged the daily neural biomarkers
293 belonging to the same week to compute the weekly neural biomarkers. We next

294 correlated the weekly neural biomarker values with the weekly HAMD, MADRS, and
295 HAMA scores, respectively, using Spearman's rank correlation analyses with
296 explained variance (EV) as an estimation. We further analyzed the temporal dynamics
297 in the neural biomarker and symptoms, using the dynamic time warping (DTW)
298 distance [58] to measure the temporal tracking ability of the neural biomarker. Both
299 the neural biomarker values and the symptom scales were normalized to a range of 0
300 to 1. We used a size three Sakoe–Chiba warping window in the DTW analysis
301 following prior work [17,59]. A smaller DTW distance represents better temporal
302 tracking. To determine the significance of the computed DTW distance, we randomly
303 shuffled the temporal sequence of the neural biomarker 10,000 times and used the
304 corresponding shuffled DTW distances as the null hypothesis distribution for
305 computing the P value.

306 Second, we investigated tracking the temporal dynamics of the daily VAS-D and
307 VAS-A self-reports, which were also not used in neural biomarker identification.
308 Similar to the weekly case, daily LFP features were used to generate daily neural
309 biomarkers, which were then correlated with daily VAS-D and VAS-A reports. DTW
310 was again used to assess the temporal tracking of daily depression symptom variations.

311 Third, we qualitatively compared trends in weekly neural biomarkers and
312 depression ratings across three DBS frequency alterations (1 Hz to Off-2, Off-2 to 20
313 Hz, 20 Hz to 130 Hz). We used the two-sided Wilcoxon rank-sum test to check whether
314 there was a significant difference between the two stages before and after alteration.
315 We also averaged the neural biomarker values and depression ratings across five time
316 periods for each case: 1) from the beginning of this stage to two weeks before the
317 alteration week; 2) during the week before the alteration week; 3) during the alteration

318 week; 4) during one week after the alteration week; 5) averaged from two weeks after
319 the alteration week to the end of this stage.

320 **2.9 Interpretation of the neural biomarker**

321 We then conducted multiple analyses to interpret the neurobiological implications
322 of the identified neural biomarker. First, we recognized the most contributing spectral
323 and temporal LFP features of the neural biomarker. To evaluate their contributions,
324 we performed individual classification of the high and low symptom states using each
325 feature separately. The performance of the classification provided an indication of the
326 level of information contained within each feature regarding the symptom state. To
327 further validate the contribution of these features, we compared the weights of each
328 feature in the neural biomarker identification model (see Section 2.7).

329 Second, we related the neural biomarker to the LHb E/I balance. Following prior
330 work [60], we computed the LFP spectrum's $1/f$ slope as a quantitative indicator of
331 E/I balance, where a larger absolute $1/f$ slope indicates more inhibition. More
332 specifically, after calculating the PSD of the remaining epochs after the removal of
333 bad epochs (see Section 2.5), we averaged the spectrum across LFP epochs within the
334 same day and selected a frequency range of interest to be 1-30 Hz (our signal spectrum
335 range). We then estimated $1/f$ slope from the log-transformed PSD using linear
336 regression, with the coefficient representing the $1/f$ slope. We next normalized the E/I
337 indicator by computing the percentage change relative to the $1/f$ slope of the first LFP
338 recording day. We finally correlated this E/I indicator with the identified neural
339 biomarker and its most contributing features using standard Spearman's rank
340 correlation analyses.

341 **3. Results**

342 **3.1 LHb DBS improved the patient’s depression symptoms,**
343 **emotional blunting, and cognitive functions**

344 We first examined the TRD patient’s depression and anxiety symptom changes
345 throughout the LHb DBS treatment process. At the beginning of treatment, the
346 patient’s baseline HAMD score was 20, MADRS score was 25, and HAMA score
347 was 16. In terms of the weekly clinical ratings (Table 1 and Figure 3A), the patient
348 responded at week 14 (HAMD score dropped to 10; MADRS score dropped to 19;
349 HAMA score dropped to 8) and achieved remission by the end of the 41-week
350 treatment (HAMD score was 7; MADRS score was 9; HAMA score was 6). The daily
351 self-reports followed a similar decreasing trend (Figure 3B). Such a consistent trend
352 was confirmed by the strong positive correlation between the daily self-reports and
353 weekly clinical ratings (Spearman’s $\rho > 0.5$, $P < 0.05$ for all pair-wise
354 correlations; see Table S2 and Figure S1 for details).

355 **Table 1. Assessment of depression and anxiety symptoms with weekly clinical**
356 **ratings. mean \pm s.e.m.**

Weekly clinical ratings	LHb DBS treatment stage				
	Baseline N=1	1Hz N=4	Off-2 N=3	20Hz N=15	130Hz N=14
HAMD	20	11.00 \pm 0.41	12.33 \pm 0.88	9.20 \pm 0.46	6.86 \pm 0.25
MADRS	25	18.75 \pm 0.48	21.00 \pm 1.00	17.93 \pm 0.63	10.64 \pm 0.56
HAMA	16	9.75 \pm 0.48	11.67 \pm 0.33	9.80 \pm 0.39	8.29 \pm 0.38

357




Figure 3. Changes of weekly and daily symptom scores during the LHb DBS treatment. (A) Changes of weekly clinical ratings during the treatment. The vertical dashed lines represent different treatment stages indicated by the x-axis labels. (B) Changes of daily self-reports during the treatment. The vertical dashed lines represent different treatment stages indicated by the x-axis labels.

358 Besides alleviating depression and anxiety symptoms as indicated by the weekly
 359 clinical ratings and daily self-reports, LHb DBS also improved the patient's emotional
 360 blunting and cognitive functioning. The total scores of ODQ dropped from the
 361 presurgery baseline of 117 to 94, and most of the ODQ subdomains continuously
 362 decreased during the DBS treatment (Table 2), indicating an improvement of
 363 emotional blunting. MCCB and THINC-it as cognitive function instruments
 364 suggested cognitive performance improved compared to the presurgery baseline
 365 (Table 3). Specifically, in the MCCB test, persistent improvements were found in
 366 processing speed, verbal learning, visual learning, reasoning/problem solving, and
 367 social cognition, while attention and working memory temporarily improved but
 368 fluctuated during the treatment. In the THINC-it test, the performance of Symbol
 369 check and Trail task, which were highly related to working memory [61] and

370 executive functioning [62], showed persistent improvements, while PHQ-D-5,
 371 Spotter, and CodeBreaker task performance fluctuated.

372 **Table 2. Assessment of emotional blunting with Oxford Depressive Symptoms**
 373 **Questionnaire (ODQ).**

Domains of ODQ	Follow up after activation of stimulation			
	Baseline	69 days	173 days	270 days
General Reduction	23	24	23	19
Reduction in Positive	25	25	24	20
Emotional Detachment	25	25	16	18
Not Caring	22	23	18	18
Antidepressant as Cause	22	22	18	19
Total	117	119	99	94

374 **Table 3. Assessment of cognitive functioning with MATRICS Consensus**
 375 **Cognitive Battery (MCCB) and THINC-it.**

	Domains of MCCB	Follow up after activation of stim.		
		Baseline	173 days	271 days
MATRICS Consensus Cognitive Battery	Processing Speed	27	55	55
	Attention/Vigilance	24	41	37
	Working Memory	47	58	52
	Verbal Learning	36	40	43
	Visual Learning	52	63	63
	Reasoning/Problem Solving	30	44	42
	Social Cognition	25	29	28
	Domains of THINC-it	Follow up after activation of stim.		
		Baseline	69 days	271 days
THINC-it	PHQ-D-5	600	400	1000
	Spotter (Reaction time)	2128	2192	656
	Symbol check (N-back)	1332	2000	2334
	CodeBreaker (Digit symbol substitution)	850	1150	950
	Trails (Trail making test)	1103	2096	2191

376 **3.2 Multiple spectral and temporal Lhb LFP features**

377 **significantly correlated with symptom changes**

378 During the Lhb DBS treatment process, we recorded daily Lhb LFP signals.

379 Therefore, we then investigated how the LFP features correlated with the patient's

380 symptom changes (Figure 4A). We found that many of the temporal and spectral

381 domain Lhb LFP features were significantly correlated with the weekly clinical




Figure 4. Correlations between the symptom evaluations (weekly and daily symptom scores) and the LFP features (temporal and spectral domain features). (A) Schematic diagram of correlation analysis. (B) Heatmap of the correlation coefficients. Each cell shows the correlation coefficient (CC) value between one LFP feature (y-axis) and one symptom score (x-axis), and cells marked with * indicate the coefficients that are significantly different from zero (Bonferroni corrected $p < 0.05$). (C) Positive and negative correlation examples with the weekly HAMD score and daily VAS-D score as shown by the yellow boxes in (B).

382 ratings and daily self-reports (Figure 4B). For example, Hurst exponent exhibited the
383 strongest correlations with both weekly HAMD scores and daily VAS-D scores
384 (Figure 4C). The results indicate that it is feasible to identify an LHb neural biomarker
385 of depression symptoms from the LFP temporal and spectral domain features.

386 **3.3 Accurate classification of high and low symptom severity** 387 **states led to the identification of an LHb neural biomarker**

388 We next used the LFP temporal and spectral features to identify a neural biomarker
389 that can classify high and low depression symptom severity states (Figure 5A). We
390 started by defining a state of high symptom severity and a state of low symptom
391 severity via clustering the weekly depression scales HAMD and MADRS (Figure 5B).
392 The high symptom state (7 weeks) had an average HAMD score of 12.8 and an
393 average MADRS score of 22.5, while the low symptom state (4 weeks) had an
394 average HAMD score of 6.3 and an average MADRS score of 9.0. We then used LFP
395 temporal domain and spectral domain features from these 11 weeks to classify the
396 high and low symptom severity states via six machine learning models in cross-
397 validation. Among these six models, the LR model performed better than other more
398 complicated models (Figure 5C and table S3). Specifically, for the LR model, the
399 cross-validated classification accuracy was 0.973 ± 0.002 (mean \pm s.e.m.), the
400 specificity was 0.961 ± 0.003 , the sensitivity was 0.988 ± 0.002 , the F1-score was
401 0.970 ± 0.002 , and the AUC score was 0.974 ± 0.001 , which were all significantly
402 higher than other models (Wilcoxon rank sum test, Bonferroni corrected $P < 0.05$ for
403 all comparisons), suggesting that the LR model was best suited for classifying the
404 collected data. We thus selected the LR model for further analyses. Then, we retrained




Figure 5. Accurate classification of high and low depression symptom severity states by the identified neural biomarker. (A) Schematic diagram of neural biomarker identification. Note that the identification was conducted using supervised learning and cross-validation purely based on the weekly data in the high and low symptom states. The rest weekly data in the transition symptom state were used later to test the tracking performance of the identified neural biomarker. (B) Clustering of depression symptom severity states. We clustered the HAMD and MADRS scores to obtain three distinct symptom states: a high depression symptom severity state (shaded in red), a low depression symptom severity state (shaded in blue), and a transition state (shaded in grey). Each point represents data of a week. The average HAMD and MADRS scores of the high and low clusters are also indicated in the figure. (C) Classification performance of different classifiers. The bar represents mean and the whiskers represent the 95% confidence interval. Six classification models (different colors) were compared in terms of five performance matrices (different x-axis groups): accuracy, specificity, sensitivity, F1-Score and AUC. The best model was indicated by a yellow star for each metric. Classification model abbreviations: logistic regression (LR), multilayer perceptron (MLP), adaptive boosting (AdaBoost), support vector machine (SVM), random forest (RF), and linear discriminant analysis (LDA).

405 the LR model using the 11 weeks' labeled data, resulting in the neural biomarker
 406 model, which model took the LFP features as input and output the model decision
 407 value as the neural biomarker, with higher values indicating worse symptoms.

408 **3.4 The identified neural biomarker simultaneously tracked the**
409 **temporal dynamics of weekly and daily depression symptom**
410 **variations during LHb DBS treatment**

411 After identifying the neural biomarker of depression symptoms, we evaluated its
412 ability to track the temporal dynamics of slow (weekly) and fast (daily) depression
413 symptom variations during the LHb DBS treatment. For slow weekly variations, we
414 used the identified neural biomarker model to compute weekly neural biomarker
415 values (see Section 2.8). We used the weekly neural biomarker values to predict the
416 associated weekly clinical ratings, where we strictly excluded the weekly data that
417 were used to identify the neural biomarker (i.e., the prediction was based on unseen
418 transition symptom state data not used in training the neural biomarker model, Figure
419 6A). We found that the weekly neural biomarker values significantly predicted the
420 HAMD scores (Figure 6B, $EV=0.74$, $P = 1.1 \times 10^{-5}$). Further, considering the
421 temporal dynamics in detail by using the DTW distance analysis (see Section 2.8),
422 we found that the weekly neural biomarker significantly tracked the temporal
423 dynamics of weekly HAMD score variations (random shuffle $P = 0.00001$).
424 Consistently, the weekly neural biomarker values significantly predicted the MADRS
425 scores (Figure 6C, $EV=0.34$, $P = 0.039$), and tracked the temporal dynamics in the
426 DTW distance analysis with marginally significant statistics (random shuffle $P =$
427 0.1079). Conversely, the weekly neural biomarker values did not predict the HAMA
428 scores (Figure 6D, $EV=0.03$, $P = 5.2 \times 10^{-1}$) or tracked the temporal dynamics
429 (random shuffle $P = 0.5865$).

430




Figure 6. Accurate tracking of the temporal dynamics of weekly depression symptom variations by the identified neural biomarker. (A) Schematic diagram of analyzing the neural biomarker’s weekly tracking performance. The neural biomarker, derived from the training data of weekly high and low symptom states, was tested by tracking the unseen weekly clinical ratings of transition symptom state. (B) Left: correlation between the identified neural biomarker values and the weekly HAMD scores. CC: correlation coefficient. EV: Explained variance. Middle: neural biomarker tracking of the weekly HAMD score dynamics over time. Right: the DTW distance analysis result for evaluating the significance of tracking in the middle panel. Smaller DTW distance represents better tracking. Note that we normalized both the neural biomarker values and the symptom scales to a range of 0 to 1 using min-max normalization for better visualization. (C) same as (B) but for the weekly MADRS scores. (D) same as (B) but for the weekly HAMA scores.

431 For fast daily variations, we used the identified neural biomarker model to
 432 compute daily neural biomarker values and used the daily neural biomarker values to
 433 predict the associated daily self-reports (again, data not used in training the neural
 434 biomarker model, Figure 7A). We found that the daily neural biomarker values




Figure 7. Accurate tracking of the temporal dynamics of daily depression symptom variations by the identified neural biomarker. (A) Schematic diagram of analyzing the neural biomarker's daily tracking performance. The neural biomarker, derived from the training data of weekly high and low symptom states, was tested by tracking the unseen daily self-reports. (B) Left: correlation between the identified neural biomarker values and the daily VAS-D scores unseen in neural biomarker identification. EV: Explained variance. Middle: neural biomarker tracking of the daily VAS-D score dynamics over time. Right: the DTW distance analysis result for evaluating the significance of tracking in the middle panel. Smaller DTW distance represents better tracking. (C) same as (B) but for the daily VAS-A scores.

435 significantly predicted the VAS-D scores (Figure 7B, $EV=0.63$, $P = 1.3 \times 10^{-27}$)
 436 and showed significant tracking of VAS-D dynamics (random shuffle $P = 0.0001$).
 437 By contrast, while the daily neural biomarker values predicted the VAS-A scores
 438 (Figure 7C, $EV=0.51$, $P = 5.3 \times 10^{-16}$) but the daily neural biomarker did not
 439 significantly track VAS-A dynamics (random shuffle $P = 1.00$).

440

441 In summary, the results show that the identified neural biomarker significantly
442 tracked the temporal dynamics of both weekly and daily variations in depression
443 symptoms during the LHb DBS treatment and specifically tracked depression
444 symptoms rather than anxiety symptoms.

445 **3.5 The identified neural biomarker reflected changes of** 446 **depression symptoms in response to DBS parameter** 447 **alterations**

448 A useful neural biomarker for DBS also needs to reflect the effect of different DBS
449 parameters. We thus evaluated if the identified neural biomarker could reflect changes
450 in depression symptoms in response to DBS parameter alterations. We applied three
451 different DBS frequencies during the treatment: 1 Hz, 20 Hz, and 130 Hz. For the
452 DBS alteration from 1 Hz to stimulation off (Off-2, the DBS device shut down due to
453 unnoticed power off), there was a trend of increasing for the neural biomarker, HAMD,
454 and MADRS while the statistical tests were not significant due to the limited sample
455 size (Figure 8A, 1Hz vs. stimulation off, normalized mean \pm s.e.m., neural biomarker:
456 0.912 ± 0.055 vs. 0.956 ± 0.026 , $P=0.35$; HAMD: 0.562 ± 0.062 vs. 0.688 ± 0.036 ,
457 $P=0.16$; MADRS: 0.656 ± 0.031 vs. 0.734 ± 0.053 , $P=0.35$), which indicated a
458 rebound trend of depression symptoms due to the disruption of DBS treatment. For
459 the DBS alteration from stimulation off (Off-2) to 20 Hz stimulation, the neural
460 biomarker, HAMD, and MADRS consistently decreased (Figure 8B, stimulation off
461 vs. 20 Hz, neural biomarker: 0.905 ± 0.095 vs. 0.545 ± 0.059 , $P=0.04$; HAMD:
462 0.875 ± 0.125 vs. 0.375 ± 0.072 , $P=0.05$; MADRS: 0.875 ± 0.000 vs. 0.606 ± 0.061 ,
463 $P=0.08$). Specifically, the neural biomarker, HAMD and MADRS scores all




Figure 8. The consistent trend between the neural biomarker and the depression symptom changes when DBS frequencies were altered. (A) DBS frequency was altered from 1 Hz to Off-2. Top: comparison of the values of the biomarker, HAMD scores and MADRS scores between the 1Hz stage and Off-2 stage. Two-sided Wilcoxon rank-sum test was used for significance test. Asterisks indicate the significance $*p<0.05$ and ns indicates no significance. Row two: changes in the identified neural biomarker time-locked to the DBS frequency alteration week (vertical dashed line). Row three: changes in HAMD time-locked to the DBS frequency alteration week. Bottom: changes in MADRS time-locked to the DBS frequency alteration week. (B) same as (A) but for DBS frequency alteration from Off-2 to 20 Hz. (C) same as (A) but for DBS frequency alteration from 20 Hz to 130 Hz.

464 decreased at the week of DBS frequency alteration, further decreased one week after
 465 the alteration and continued to decrease with more obvious changes after week two.
 466 For the DBS alteration from 20 Hz to 130 Hz stimulation, the neural biomarker,
 467 HAMD, and MADRS also consistently decreased (Figure 8C, 20 Hz vs. 130 Hz,
 468 neural biomarker: 0.524 ± 0.060 vs. 0.088 ± 0.029 , $P=0.001$; HAMD: 0.323 ± 0.054 vs.
 469 0.042 ± 0.026 , $P=0.004$; MADRS: 0.573 ± 0.056 vs. 0.062 ± 0.016 , $P=0.001$). More
 470 specifically, the neural biomarker, HAMD and MADRS scores already showed a
 471 trend of decreasing before the DBS frequency alteration, and the alleviated symptoms
 472 stayed relatively stable during the alteration week, at week one after the alteration,

473 and the same stable trend continued after week two. The results suggested that the 1
474 Hz DBS did not induce an obvious change in depression symptoms, while the 20 Hz
475 and 130 Hz DBS had more meaningful effects. The results further showed that the
476 neural biomarker indeed reflected the different change patterns in depression
477 symptoms when the DBS frequencies were altered.

478 **3.6 Neural biomarker identification and testing was robust to** 479 **adequate decreasing of data sample size**

480 The neural biomarker was identified and tested by a dataset consisting of 122 days of
481 data samples. Due to the difficulty of obtaining a large amount of longitudinal data,
482 we investigated the robustness of neural biomarker identification and testing in terms
483 of data sample size decreasing. We decreased the data sample size gradually from 122
484 to 10 with a step size of 2, randomly removed data from neural biomarker
485 identification and testing for each data sample size, and then repeated the entire neural
486 biomarker classification and tracking analyses. We found that the neural biomarker
487 classification accuracy consistently maintained above 0.95 even by decreasing the
488 sample size to 70 but had a large decrease below a sample size of 40 (Figure 9A).
489 Similarly, the neural biomarker tracking performance (EV in prediction) maintained
490 relatively stable by decreasing the sample size to 70 but had much larger fluctuations
491 below a sample size of 40 (Figure 9B). These results suggest that our data sample size
492 of 122 days was sufficient to obtain a robust neural biomarker.




Figure 9. Changes of the neural biomarker identification and tracking performance by gradually decreasing the data sample size. (A) The accuracy of classifying the high and low symptom states. (B) The tracking performance of depression symptoms (weekly HAMD, weekly MADRS, and daily VAS-D).

493 **3.7 The identified neural biomarker was mainly contributed by**
 494 **the β band spectral feature and the Hurst exponent temporal**
 495 **feature**

496 Having demonstrated the usefulness and robustness of the identified neural biomarker,
 497 we next aimed to provide neurobiological interpretations for the neural biomarker
 498 from multiple aspects. We started by investigating the most contributing spectral and
 499 temporal LFP features in the neural biomarker. We recognized the most contributing
 500 spectral and temporal LFP features by separately classifying the high and low weekly
 501 symptom states using each individual spectral and temporal LFP feature (Figure 10A).
 502 The best temporal domain feature was the Hurst exponent, with a cross-validated
 503 classification accuracy of 0.93. While the best spectral domain feature was the β band
 504 PSD, with an average accuracy of 0.80. Overall, temporal domain features (average
 505 accuracy: 0.78) outperformed spectral domain features (average accuracy: 0.71).
 506 Notably, combining all the LFP features yielded superior performance compared to

507 individual features. Consistently, by investigating the logistic regression coefficients
508 of the neural biomarker model (Figure 10B), we found that the features with better
509 classification accuracy also had larger coefficients in the neural biomarker model,
510 again showing the importance of β band PSD and Hurst exponent.

511 We then examined the variations of β band PSD and Hurst exponent at the high,
512 transition and low symptom states. In terms of the spectral domain, the overall LFP
513 PSD showed obvious changes during the three symptom states (Figure 10C), with the
514 β band PSD showing a significant and consistent decrease when changing from high
515 state, to transition state, and finally to low state (Figure 10D). By contrast, no
516 significant change was found for the θ band PSD and less consistent changes was
517 found for the δ band and α band PSD (Figure 10D). In terms of the temporal domain,
518 the Hurst exponent showed an increase when changing from high state, to transition
519 state, and finally to low state (Figure 10E and 10F) while other representative
520 temporal domain features showed less obvious changes (Figure 10F). Together, these
521 results demonstrated the important contribution of the β band spectral feature and the
522 Hurst exponent temporal feature to the identification of neural biomarker and the
523 tracking of depression symptom state.




Figure 10. Importance of the β band spectral feature and the Hurst exponent temporal feature to the identification of neural biomarker and the tracking of the depression symptom state. (A) Classification accuracy of individual features and all LFP features by separately training LR models. The individual spectral domain (SD) features are in green, and their indices are ordered based on classification accuracy. The individual temporal domain (TD) features are in blue, and their indices are ordered by classification accuracy. The combination of all LFP features is in brown. The best individual feature was indicated by a yellow star for each domain. (B) The absolute coefficients of each feature in the LR model trained with all LFP features. The feature indices are the same as in (A). (C) Changes in the average LFP spectrum from the high symptom state (High) to the transition symptom state (Trans), and finally to the low symptom state (Low). (D) Changes in each of the four frequency bands with individual feature classification accuracy (Acc) indicated below. Two-sided Wilcoxon rank-sum test was used for significance test. Asterisks indicate the significance levels $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, and ns indicates no significance. (E) Changes in the temporal domain feature Hurst exponent from High to Trans to Low state. (F) Same as (D) but for four example temporal domain features.

524 **3.8 The identified neural biomarker and its contributing features** 525 **indicated changes in LHb excitatory/inhibition (E/I) balance**

526 We then interpreted the identified neural biomarker by relating it to the E/I balance
527 of LHb activity. We used the LHb LFP spectrum's $1/f$ slope as a possible indicator of
528 LHb E/I balance, where a larger absolute $1/f$ slope indicates more inhibition (see
529 Section 2.9). We found that after DBS treatment, the LHb activity changed to a more
530 inhibitory state (Figure 11A). More specifically, the LHb E/I balance indicator
531 increased when high symptom state changed to low symptom state (Figure 11B) and
532 showed a trend of increase during the entire DBS treatment process (Figure 11C),
533 consistently indicating an increase of inhibition. Moreover, we found a significant
534 positive correlation between the identified neural biomarker and the LHb E/I balance
535 indicator (Figure 11D, Spearman's $\rho = 0.78$, $P = 2.7 \times 10^{-6}$). Further, the most
536 contributing Hurst exponent temporal feature and β band spectral feature both
537 significantly correlated with the LHb E/I balance indicator (Figure 11D, Hurst
538 exponent: Spearman's $\rho = -0.80$, $P = 1.9 \times 10^{-28}$; β band PSD: Spearman's
539 $\rho = 0.20$, $P = 2.8 \times 10^{-2}$). These results suggest that LHb E/I balance changed
540 towards more inhibition following DBS treatment and our identified neural biomarker
541 and its most contributing features significantly tracked such a change in LHb E/I
542 balance.




Figure 11. Changes of E/I balance during Lhb DBS treatment and its' correlations with the identified neural biomarker and the most contributing features. (A) Overview of the Lhb E/I balance change after DBS treatment. (B) Lhb LFP spectrum's $1/f$ slope of two example days in high symptom state and low symptom state, respectively. The LFP spectrum's $1/f$ slope is taken as the E/I balance indicator. (C) Temporal trace of baseline-normalized daily Lhb E/I balance indicator. (D) Correlation between the E/I balance indicator and the identified neural biomarker (left), between the E/I balance indicator and the Hurst exponent (middle), and the E/I balance indicator and the β band PSD (right).

544 **3.9 The DBS treatment involved a critical LHb-DRN circuit that**
545 **possibly regulates depression via E/I balancing**

546 After finding a connection between the neural biomarker and LHb E/I balance, we
547 finally investigated the underlying neural circuits of LHb E/I balance. We used
548 diffusion tensor imaging to obtain white matter fibers related to LHb and found that
549 strong white matter fiber connections exist between LHb and the dorsal raphe nucleus
550 (DRN) in our patient (Figure 12A).

551 The LHb-DRN circuit is a critical pathway involved in central serotonergic
552 regulation. This circuit plays a role in regulating cognition and reward, both of which
553 are essential symptom dimensions associated with depression. The involvement of
554 the LHb-DRN circuit suggests a possible mechanism of DBS treatment in our patient
555 (also see Section 4.3). Specifically, prior studies have shown that in depressed
556 patients, the LHb activity is overly excited (unbalanced E/I towards excitation), thus
557 exerting substantial inhibition on the DRN via the inhibitory connections between
558 LHb and DRN, consequently leading to reduced serotonin output from the DRN.
559 Such a reduction in serotonin further inhibits the hippocampus and medial prefrontal
560 cortex activity, possibly asserting influence on the cognitive dimension of depression;
561 it also inhibits the nucleus accumbens activity, possibly asserting influence on the
562 reward dimension of depression (Figure 12B). Our results suggest that LHb DBS
563 treatment moved the LHb activity to a more inhibitory state, possibly restoring the
564 LHb E/I balance towards a normal state and improving the depression symptoms
565 (especially cognition functions and emotion blunting, see Section 3.1) via the critical
566 regulation pathway involving LHb and DRN.




Figure 12. Diffusion tensor imaging of the white matter tracks related to LHB and a possible regulation pathway for depression. (A) Diffusion tensor imaging of the white matter tracks related to LHB. The DBS target (left LHB) and the connected brain area (DRN) were circled in red. Note that while the right LHB was not stimulated, its related white matter fibers are also shown. (B) LHB-DRN circuit and its possible role in regulating the cognition and reward dimensions of depression symptom. Hip: hippocampus; mPFC: medial prefrontal cortex; NAc: nucleus accumbens.

567 4. Discussion

568 4.1 Improvement of depression symptoms, emotional blunting, 569 and cognitive function during DBS treatment

570 The clinical evaluation results show that our patient not only achieved improvements
571 of HAMD, MADRS, and HAMA ratings that are typically used as clinical gold
572 standard in prior DBS studies [11,13,17], but also achieved notable improvements of
573 emotional blunting and cognition functioning. Almost three-quarters of patients in the
574 acute phase of depression and one-quarter of those in remission reported severe
575 emotional blunting. Approximately 56% of patients considered their emotional
576 blunting to be caused by their depression, while 45% believed that their
577 antidepressant medication was negatively affecting their emotions [63]. Emotional
578 blunting has a substantial negative impact on patients' daily functioning, well-being,
579 and quality of life in both the acute and remission phases of depression [64]. On the

580 other hand, cognitive deficits may be inherent to TRD and occur independently of
581 affective symptomatology [65]. Objective cognitive assessment for the clinical
582 evaluation for patients with TRD is important [66]. Thus, in our TRD patient, we
583 specifically addressed the evaluation of both emotional blunting and cognitive
584 functioning and showed improvements along both aspects.

585 However, our results regarding emotional blunting and cognitive functioning
586 should be interpreted cautiously because of the lack of controlled data. Due to limited
587 data about cognition in this case, we did not identify a neural biomarker to classify
588 these cognitive states. The cognitive impact of DBS has usually been previously
589 evaluated for epilepsy, movement disorder, and obsessive-compulsive disorder
590 patients but rarely in controlled studies on TRD. Our study found no cognitive decline
591 and suggests positive effects of DBS on cognitive functioning in TRD consistent with
592 a previous report [67].

593 **4.2 A data-driven Lhb neural biomarker for tracking slow and** 594 **fast depression symptom variations during DBS treatment**

595 A mechanism-driven neural biomarker for depression is currently lacking mainly
596 because the neural circuitry underlying depression has not been clearly delineated
597 [68]. Therefore, current neural biomarkers of depression symptoms for tracking DBS
598 effects have largely used data-driven machine learning methods to map LFP features
599 to depression symptom ratings [17,32,33]. The usefulness of data-driven neural
600 biomarkers critically depends on the type of data used to identify the neural biomarker.
601 For example, a recent work [32] focused on a cingulate neural biomarker that was
602 trained with and accordingly predicted longer-term (on the time scale of weeks)

503 clinical ratings. On the other hand, another recent work [17] only trained and tested a
504 neural biomarker with shorter-term (on the time scale of minutes) self-reports. Our
505 work is unique in that, while we identified our LHb neural biomarker based on weekly
506 clinical ratings, we demonstrated that the neural biomarker predicted not only weekly
507 clinical ratings (data not used in identification) but also daily self-reports (data again
508 not used in identification). The results suggest that our LHb neural biomarker could
509 track the temporal dynamics of both slow and fast depression symptom variations,
510 which was useful for developing new aDBS strategies that are robust across different
511 time scales. It is worth noting that our LHb neural biomarker specifically tracked the
512 temporal dynamics of weekly and daily depression symptom scores but not the
513 anxiety symptom scores. It suggests that despite the overlapping of depression-related
514 and anxiety-related brain networks [69], LHb neural activity is mainly related to
515 depression, which is supported by prior animal studies [21–23].

516 Both population-level and personalized neural biomarkers of depression
517 symptoms have been identified for tracking DBS effects. Population-level neural
518 biomarkers are derived from data collected from several patients and have the benefits
519 of being directly applicable to a new patient and robust interpretability of the neural
520 biomarker's biophysical mechanism across patients [32]. By contrast, personalized
521 neural biomarkers are derived from data collected from an individual patient, which
522 is more powerful in capturing the unique characteristics of depression symptoms in
523 each patient, especially given the large inter-individual variability in depression-
524 related brain networks [70]. With the emerging capability of recording more data
525 within a single patient using mobile devices, personalized neural biomarker models
526 can be more accurate in tracking the temporal dynamics of depression symptom

527 variations. With such trends, a personalized neural biomarker has been identified and
528 used for realizing aDBS targeting VC/VS [17]. Our study identified a personalized
529 neural biomarker that achieved accurate classification and tracking of depression
530 symptom variations during the DBS treatment targeting LHB, confirming the
531 usefulness of personalization. Nevertheless, population-level and personalized neural
532 biomarkers can complement each other. For example, one can leverage a large amount
533 of population data to train an interpretable population-level neural biomarker model,
534 followed by fine-tuning with personalized data to further improve its accuracy, which
535 is an important future research direction.

536 A critical issue in identifying data-driven neural biomarker, especially
537 personalized neural biomarker, is the collection of sufficient amounts of data. A recent
538 population-level study collected LFP and clinical rating data from 5 individuals on a
539 weekly basis over a span of 24 weeks [32], resulting in a total data sample size of 120,
540 which was deemed sufficient for obtaining a neural biomarker at the population level.
541 Several personalized studies collected LFP or iEEG and self-report data over several
542 days, with a data sample size of around 30 for each individual [17,33]. By contrast,
543 our study involved daily data collection over a much longer period of 41 weeks. Even
544 after removing noisy data epochs, our data-driven neural biomarker analyses were
545 based on a substantial data sample size of 122 days, which significantly exceeded the
546 data sample size of one individual in the aforementioned studies. Our robustness
547 analyses confirmed the sufficiency of our data sample size, showing that in our patient,
548 the neural biomarker performance maintained stable even after reducing the data
549 sample size to around 70 but had significant variations after reducing the data sample
550 size below 40. This result indicates the importance of collecting sufficient data for

551 identifying personalized neural biomarkers. The ongoing advancements in data
552 recording devices offer exciting prospects for recording more data samples within an
553 individual, thus facilitating the future development of personalized neural biomarkers.

554 **4.3 Neurobiological interpretation of the identified neural** 555 **biomarker and its contributing features in terms of LHb E/I** 556 **balance**

557 Previous studies have exclusively used LFP spectral domain features to identify
558 neural biomarkers for depression [17,32,33]. By contrast, we found that both the LFP
559 temporal domain and spectral domain features contributed to our neural biomarker
560 and that the temporal domain features contributed relatively more than the spectral
561 domain features. The main contributing temporal domain feature was the Hurst
562 exponent. The Hurst exponent mainly indicates the stochasticity and predictability of
563 a time-series [71]. We found that during the high and transition symptom states, the
564 LHb LFP Hurst exponent values were mostly below 0.5, which indicated more
565 stochastic and random-walk-like neural dynamics [72]. By contrast, during the low
566 symptom state towards the end of DBS treatment, the LHb LFP Hurst exponent values
567 were approaching and even surpassing 0.5, which indicated more predictable and
568 stable neural dynamics [73]. Stochastic vs. predictable neural dynamics have been
569 reported to relate with E/I balance of neural firing [74]. Related to this explanation,
570 Hurst exponent has been widely used to examine E/I balance of the neural circuits in
571 other neuropsychiatric disorders such as autism [75,76]. Our results suggest that a
572 DBS-induced increase in LHb inhibition led to an increase in the Hurst exponent,
573 moving LHb activity to a more E/I balanced state.

574 The main contributing spectral domain feature was the β band PSD. The LHb β
575 band oscillation was also found to correlate with depression symptoms before DBS
576 treatment in a previous study [28]. The β band oscillation might reflect the abnormal
577 E/I balance of LHb neural ensembles underlying depression because it can depend on
578 the firing patterns of a network of inhibitory interneurons gated by their mutually
579 induced GABA_A action [77]. Moreover, LHb β band oscillation might be related to
580 the abnormal burst spiking phenomena of LHb neurons found in rodents exhibiting
581 depression-like behaviors [21–23]. These findings highlight the significance of the β
582 band oscillations in LHb as related to depression.

583 Existing neuroscience findings provide evidence that LHb E/I balance
584 influences the dopaminergic and serotonergic projections from LHb and directly
585 affects two neural pathways: the LHb-VTA (ventral tegmental area) pathway mainly
586 regulates the dopaminergic activity, while the LHb-DRN pathway primarily regulates
587 the serotonergic activity [34]. Our white fiber tracking results predominantly
588 reflected the influence of DBS on the LHb-DRN pathway. The DBS might have
589 inhibited overly-excited LHb activity, activating overly-inhibited DRN activity, and
590 restoring downstream neural activity related to cognition and reward circuits related
591 to depression, which finally led to the multi-faceted improvement of depression
592 symptoms, emotional blunting, and cognitive functioning of our patient. However,
593 due to the complexity of LHb-related circuits, the exact neural activity changes of the
594 LHb-related circuit in DBS treatment of depression requires further investigation by
595 collecting multimodal neural data from more brain regions.

596 It is worth noting that due to the limitation of DBS electrode, we only used a
597 simple LFP $1/f$ slope as an indirect indicator for LHb E/I balance. The E/I balance is

598 directly related to the spiking activity of excitatory neurons and inhibitory neurons,
599 and further related to the neuronal homeostasis and the formation of neural
700 oscillations [78,79]. The underlying excitatory and inhibitory neuron synaptic
701 currents mix together to give rise to the $1/f$ -like nature of the LFP PSD [34]. Previous
702 study found that alterations of E/I balance within neural circuits can indeed be inferred
703 from changes in the LFP $1/f$ slope [80]. Nevertheless, the LFP signal represents the
704 collective activity of multiple neurons and only provides an indirect measure of E/I
705 balance. Future work can use more advanced micro-macro electrodes [81] to record
706 LHb spiking activity to more directly quantify LHb E/I balance.

707 **4.4 DBS frequency differentially modulates the depression** 708 **symptom and neural biomarker**

709 Prior studies have shown that DBS frequency can significantly influence the treatment
710 efficacy for TRD, e.g., high-frequency DBS has generally yielded better treatment
711 outcomes than low-frequency DBS [24,82,83]. Consistently, we discovered that a
712 very low DBS frequency of 1 Hz was not effective in alleviating the depression
713 symptoms in our patient, but higher frequencies of 20 Hz and 130 Hz were more
714 effective. Beyond the depression symptom ratings, we additionally found that the
715 neural biomarker was also consistently modulated by the different DBS frequencies.
716 DBS frequency might influence the release of neurotransmitters in depression-
717 targeted pathways [84], thus modulating the neural biomarker and the depression
718 symptoms. However, similar to other DBS targets, the optimal DBS frequency at LHb
719 is still also an open question that requires further research.

720 **5. Limitations**

721 Our study has several limitations. First, while our study had a sufficient within-patient
722 data sample size, the patient sample size was limited (n-of-1); further studies with
723 more patients are needed to confirm our findings on LHb neural biomarkers. Second,
724 despite its powerful classification and tracking performance, our neural biomarker
725 was identified using only one channel of LFP signals due to the limitation of device
726 hardware configuration. Incorporating multi-channel LFP signals in future studies
727 would allow for finding neural biomarkers with even better performance and a more
728 comprehensive understanding of the neural mechanism underlying neural biomarker
729 identification. Third, due to the high-frequency recording noise of our DBS device,
730 we filtered the LFP signal below 30 Hz to ensure noise rejection. Future work with
731 better recording capability should investigate how higher-frequency LFP temporal
732 and spectral domain features contribute to the identification of neural biomarkers.
733 Finally, to remove the confounding factor of stimulation artifact, when we recorded
734 LFP, we completely turned off stimulation. While this approach ensured stimulation-
735 artifact-free LFP signals, it is important to consider using LFP signals during
736 stimulation to identify better responsive neural biomarkers in the future, but this
737 requires high-performance stimulation artifact removal, which remains challenging
738 [85].

739 **6. Conclusion**

740 One patient with TRD reached remission after 41 weeks of LHb DBS treatment. With
741 a unique longitudinal data collection of concurrent daily and weekly depression

742 symptom scores and LHb LFP signals during the entire treatment process, we used
743 machine learning to identify an LHb neural biomarker of depression symptoms, with
744 the most contributing spectral feature being LFP β band power and temporal feature
745 being Hurst exponent. We demonstrated that our LHb neural biomarker accurately
746 classified high and low depression symptom severity states, simultaneously tracked
747 the temporal dynamics of weekly (slow) and daily (fast) depression symptom
748 variations during the DBS treatment process, and reflected the depression symptom
749 changes in response to DBS frequency alterations. We also interpreted the neural
750 biomarker as indicating changes in LHb excitatory/inhibition balance during DBS
751 treatment. Our methods and results hold promise in identifying clinically-viable
752 neural biomarkers to facilitate future adaptive DBS developments for treating TRD.

753 **Data availability**

754 The data supporting this study's findings are available from the corresponding author
755 upon reasonable request.

756 **Funding**

757 This work was supported in part by the National Natural Science Foundation of China
758 under Grants 62336007, 62306269 and 62476239, in part by the Zhejiang Provincial
759 Natural Science Foundation of China under Grant LD24H090001, in part by the
760 Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced
761 Study under Grant SN-ZJU-SIAS-002, and in part by the Fundamental Research
762 Funds for the Central Universities under Grant 226-2024-00127.

763 **Author Contributions**

764 Shi Liu: Methodology, Software, Formal analysis, Writing - Original Draft,
765 Visualization. Yu Qi: Investigation, Resources. Shaohua Hu: Conceptualization,
766 Resources. Ning Wei: Resources, Data Curation, Writing - Original Draft. Jianmin
767 Zhang: Conceptualization, Resources. Junming Zhu: Conceptualization, Resources.
768 Hemmings Wu: Conceptualization, Investigation. Hailan Hu: Conceptualization.
769 Yuxiao Yang: Conceptualization, Supervision, Methodology, Writing - Review &
770 Editing, Funding acquisition. Yueming Wang: Conceptualization, Supervision,
771 Project administration, Funding acquisition, Writing - Review & Editing. All authors
772 revised and approved the final version of the manuscript.

773 **Conflict of Interest**

774 There are no financial conflicts of interest to disclose.

775 **References**

- 776 [1] Organization WH, others. Depression and other common mental disorders:
777 global health estimates. World Health Organization; 2017.
- 778 [2] Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major
779 depressive disorder. *Nat Rev Dis Primers* 2016;2:16065.
780 <https://doi.org/10.1038/nrdp.2016.65>.
- 781 [3] Krauss JK, Lipsman N, Aziz T, Boutet A, Brown P, Chang JW, et al.
782 Technology of deep brain stimulation: current status and future directions. *Nat*
783 *Rev Neurol* 2021;17:75–87. <https://doi.org/10.1038/s41582-020-00426-z>.
- 784 [4] Dandekar MP, Fenoy AJ, Carvalho AF, Soares JC, Quevedo J. Deep brain
785 stimulation for treatment-resistant depression: an integrative review of
786 preclinical and clinical findings and translational implications. *Mol Psychiatry*
787 2018;23:1094–112. <https://doi.org/10.1038/mp.2018.2>.

- 788 [5] Figeé M, Riva-Posse P, Choi KS, Bederson L, Mayberg HS, Kopell BH. Deep
789 Brain Stimulation for Depression. *Neurotherapeutics* 2022;19:1229–45.
790 <https://doi.org/10.1007/s13311-022-01270-3>.
- 791 [6] Johnson KA, Okun MS, Scangos KW, Mayberg HS, de Hemptinne C. Deep
792 brain stimulation for refractory major depressive disorder: a comprehensive
793 review. *Mol Psychiatry* 2024:1–13. [https://doi.org/10.1038/s41380-023-](https://doi.org/10.1038/s41380-023-02394-4)
794 [02394-4](https://doi.org/10.1038/s41380-023-02394-4).
- 795 [7] Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C,
796 et al. Deep Brain Stimulation for Treatment-Resistant Depression. *Neuron*
797 2005;45:651–60. <https://doi.org/10.1016/j.neuron.2005.02.014>.
- 798 [8] Malone DA, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar
799 EN, et al. Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for
800 Treatment-Resistant Depression. *Biol Psychiatry* 2009;65:267–75.
801 <https://doi.org/10.1016/j.biopsych.2008.08.029>.
- 802 [9] Schlaepfer TE, Bewernick BH, Kayser S, Mädler B, Coenen VA. Rapid Effects
803 of Deep Brain Stimulation for Treatment-Resistant Major Depression. *Biol*
804 *Psychiatry* 2013;73:1204–12. <https://doi.org/10.1016/j.biopsych.2013.01.034>.
- 805 [10] Neumann W-J, Huebl J, Brücke C, Gabriëls L, Bajbouj M, Merkl A, et al.
806 Different patterns of local field potentials from limbic DBS targets in patients
807 with major depressive and obsessive compulsive disorder. *Mol Psychiatry*
808 2014;19:1186–92. <https://doi.org/10.1038/mp.2014.2>.
- 809 [11] Bergfeld IO, Mantione M, Hoogendoorn MLC, Ruhe HG, Notten P, van
810 Laarhoven J, et al. Deep Brain Stimulation of the Ventral Anterior Limb of the
811 Internal Capsule for Treatment-Resistant Depression A Randomized Clinical
812 Trial. *Jama Psychiatry* 2016;73:456–64.
813 <https://doi.org/10.1001/jamapsychiatry.2016.0152>.
- 814 [12] Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT, O’Reardon
815 JP, et al. A Randomized Sham-Controlled Trial of Deep Brain Stimulation of
816 the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant
817 Depression. *Biol Psychiatry* 2015;78:240–8.
818 <https://doi.org/10.1016/j.biopsych.2014.11.023>.
- 819 [13] Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA,
820 McClintock S, et al. Subcallosal cingulate deep brain stimulation for treatment-
821 resistant depression: a multisite, randomised, sham-controlled trial. *Lancet*
822 *Psychiatry* 2017;4:839–49. [https://doi.org/10.1016/S2215-0366\(17\)30371-1](https://doi.org/10.1016/S2215-0366(17)30371-1).
- 823 [14] Coenen VA, Bewernick BH, Kayser S, Kilian H, Boström J, Greschus S, et al.
824 Superolateral medial forebrain bundle deep brain stimulation in major
825 depression: a gateway trial. *Neuropsychopharmacology* 2019;44:1224–32.
826 <https://doi.org/10.1038/s41386-019-0369-9>.
- 827 [15] Raymaekers S, Luyten L, Bervoets C, Gabriëls L, Nuttin B. Deep brain
828 stimulation for treatment-resistant major depressive disorder: a comparison of

329 two targets and long-term follow-up. *Transl Psychiatry* 2017;7:e1251–e1251.
330 <https://doi.org/10.1038/tp.2017.66>.

331 [16] Guidetti M, Marceglia S, Loh A, Harmsen IE, Meoni S, Foffani G, et al.
332 Clinical perspectives of adaptive deep brain stimulation. *Brain Stimul*
333 2021;14:1238–47. <https://doi.org/10.1016/j.brs.2021.07.063>.

334 [17] Scangos KW, Khambhati AN, Daly PM, Makhoul GS, Sugrue LP, Zamanian
335 H, et al. Closed-loop neuromodulation in an individual with treatment-resistant
336 depression. *Nat Med* 2021;27:1696–700. [https://doi.org/10.1038/s41591-021-](https://doi.org/10.1038/s41591-021-01480-w)
337 [01480-w](https://doi.org/10.1038/s41591-021-01480-w).

338 [18] Hu H, Cui Y, Yang Y. Circuits and functions of the lateral habenula in health
339 and in disease. *Nat Rev Neurosci* 2020;21:277–95.
340 <https://doi.org/10.1038/s41583-020-0292-4>.

341 [19] Roman E, Weininger J, Lim B, Roman M, Barry D, Tierney P, et al. Untangling
342 the dorsal diencephalic conduction system: a review of structure and function
343 of the stria medullaris, habenula and fasciculus retroflexus. *Brain Struct Funct*
344 2020;225:1437–58. <https://doi.org/10.1007/s00429-020-02069-8>.

345 [20] Dai D, Li W, Chen A, Gao X-F, Xiong L. Lateral Habenula and Its Potential
346 Roles in Pain and Related Behaviors. *ACS Chem Neurosci* 2022;13:1108–18.
347 <https://doi.org/10.1021/acchemneuro.2c00067>.

348 [21] Cui Y, Yang Y, Dong Y, Hu H. Decoding Depression: Insights from Glial and
349 Ketamine Regulation of Neuronal Burst Firing in Lateral Habenula. *Cold*
350 *Spring Harb Symp Quant Biol* 2018;83:141–50.
351 <https://doi.org/10.1101/sqb.2018.83.036871>.

352 [22] Cui Y, Yang Y, Ni Z, Dong Y, Cai G, Foncelle A, et al. Astroglial Kir4.1 in the
353 lateral habenula drives neuronal bursts in depression. *Nature* 2018;554:323–7.
354 <https://doi.org/10.1038/nature25752>.

355 [23] Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in
356 the lateral habenula to rapidly relieve depression. *Nature* 2018;554:317–22.
357 <https://doi.org/10.1038/nature25509>.

358 [24] Sartorius A, Kiening KL, Kirsch P, Gall CC von, Haberkorn U, Unterberg AW,
359 et al. Remission of Major Depression Under Deep Brain Stimulation of the
360 Lateral Habenula in a Therapy-Refractory Patient. *Biol Psychiatry* 2010;67:e9–
361 11. <https://doi.org/10.1016/j.biopsych.2009.08.027>.

362 [25] Wang Z, Cai X, Qiu R, Yao C, Tian Y, Gong C, et al. Case Report: Lateral
363 Habenula Deep Brain Stimulation for Treatment-Resistant Depression. *Front*
364 *Psychiatry* 2021;11. <https://doi.org/10.3389/fpsy.2020.616501>.

365 [26] Kiening K, Sartorius A. A new translational target for deep brain stimulation to
366 treat depression. *EMBO Molecular Medicine* 2013;5:1151–3.
367 <https://doi.org/10.1002/emmm.201302947>.

368 [27] Zhang C, Kim S-G, Li D, Zhang Y, Li Y, Husch A, et al. Habenula deep brain
369 stimulation for refractory bipolar disorder. *Brain Stimulation* 2019;12:1298–
370 300. <https://doi.org/10.1016/j.brs.2019.05.010>.

- 371 [28] Zhang C, Zhang Y, Luo H, Xu X, Yuan T, Li D, et al. Bilateral Habenula deep
372 brain stimulation for treatment-resistant depression: clinical findings and
373 electrophysiological features. *Transl Psychiatry* 2022;12:52.
374 <https://doi.org/10.1038/s41398-022-01818-z>.
- 375 [29] Wang Z, Jiang C, Guan L, Zhao L, Fan T, Wang J, et al. Deep brain stimulation
376 of habenula reduces depressive symptoms and modulates brain activities in
377 treatment-resistant depression. *Nat Mental Health* 2024.
378 <https://doi.org/10.1038/s44220-024-00286-2>.
- 379 [30] Vissani M, Isaias IU, Mazzoni A. Deep brain stimulation: a review of the open
380 neural engineering challenges. *J Neural Eng* 2020;17:051002.
381 <https://doi.org/10.1088/1741-2552/abb581>.
- 382 [31] Priori A, Maiorana N, Dini M, Guidetti M, Marceglia S, Ferrucci R. Chapter
383 Six - Adaptive deep brain stimulation (aDBS). In: Moro E, Polosan M, Hamani
384 C, editors. *Int Rev Neurobiol*, vol. 159, Academic Press; 2021, p. 111–27.
385 <https://doi.org/10.1016/bs.irn.2021.06.006>.
- 386 [32] Alagapan S, Choi KS, Heisig S, Riva-Posse P, Crowell A, Tiruvadi V, et al.
387 Cingulate dynamics track depression recovery with deep brain stimulation.
388 *Nature* 2023;1–9. <https://doi.org/10.1038/s41586-023-06541-3>.
- 389 [33] Frank AC, Scangos KW, Larson PS, Norbu T, Lee AT, Lee AM. Identification
390 of a personalized intracranial biomarker of depression and response to DBS
391 therapy. *Brain Stimul* 2021;14:1002–4.
392 <https://doi.org/10.1016/j.brs.2021.06.009>.
- 393 [34] Sonkusare S, Ding Q, Zhang Y, Wang L, Gong H, Mandali A, et al. Power
394 signatures of habenular neuronal signals in patients with bipolar or unipolar
395 depressive disorders correlate with their disease severity. *Transl Psychiatry*
396 2022;12:1–9. <https://doi.org/10.1038/s41398-022-01830-3>.
- 397 [35] Cobb BS, Coryell WH, Cavanaugh J, Keller M, Solomon DA, Endicott J, et al.
398 Seasonal variation of depressive symptoms in unipolar major depressive
399 disorder. *Compr Psychiatry* 2014;55:1891–9.
900 <https://doi.org/10.1016/j.comppsy.2014.07.021>.
- 901 [36] Panaite V, Rottenberg J, Bylsma LM. Daily Affective Dynamics Predict
902 Depression Symptom Trajectories Among Adults with Major and Minor
903 Depression. *Affect Sci* 2020;1:186–98. <https://doi.org/10.1007/s42761-020-00014-w>.
- 904 [37] Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS,
905 et al. Deep Brain Stimulation for Treatment-Resistant Depression: Follow-Up
906 After 3 to 6 Years. *Am J Psychiatry* 2011;168:502–10.
907 <https://doi.org/10.1176/appi.ajp.2010.10081187>.
- 908 [38] Bewernick BH, Kayser S, Sturm V, Schlaepfer TE. Long-Term Effects of
909 Nucleus Accumbens Deep Brain Stimulation in Treatment-Resistant
910 Depression: Evidence for Sustained Efficacy. *Neuropsychopharmacology*
911 2012;37:1975–85. <https://doi.org/10.1038/npp.2012.44>.
- 912

- 913 [39] Crowell AL, Riva-Posse P, Holtzheimer PE, Garlow SJ, Kelley ME, Gross RE,
914 et al. Long-Term Outcomes of Subcallosal Cingulate Deep Brain Stimulation
915 for Treatment-Resistant Depression. *Am J Psychiatry* 2019;176:949–56.
916 <https://doi.org/10.1176/appi.ajp.2019.18121427>.
- 917 [40] Peeters F, Berkhof J, Delespaul P, Rottenberg J, Nicolson NA. Diurnal mood
918 variation in major depressive disorder. *Emotion* 2006;6:383–91.
919 <https://doi.org/10.1037/1528-3542.6.3.383>.
- 920 [41] Wirz-Justice A. Diurnal variation of depressive symptoms. *Dialogues Clin*
921 *Neurosci* 2008;10:337–43.
922 <https://doi.org/10.31887/DCNS.2008.10.3/awjustice>.
- 923 [42] Scangos KW, Makhoul GS, Sugrue LP, Chang EF, Krystal AD. State-dependent
924 responses to intracranial brain stimulation in a patient with depression. *Nat*
925 *Med* 2021;27:229–31. <https://doi.org/10.1038/s41591-020-01175-8>.
- 926 [43] Bewernick BH, Kayser S, Gippert SM, Coenen VA, Schlaepfer TE. Acute
927 antidepressant effects of deep brain stimulation – Review and data from
928 sLMFB-stimulation. *Pers Med Psychiatry* 2017;3:1–7.
929 <https://doi.org/10.1016/j.pmip.2017.01.002>.
- 930 [44] Xiao J, Provenza NR, Asfour J, Myers J, Mathura RK, Metzger B, et al.
931 Decoding Depression Severity From Intracranial Neural Activity. *Biol*
932 *Psychiatry* 2023;94:445–53. <https://doi.org/10.1016/j.biopsych.2023.01.020>.
- 933 [45] Sani OG, Yang Y, Lee MB, Dawes HE, Chang EF, Shanechi MM. Mood
934 variations decoded from multi-site intracranial human brain activity. *Nat*
935 *Biotechnol* 2018;36:954–61. <https://doi.org/10.1038/nbt.4200>.
- 936 [46] Kirkby LA, Luongo FJ, Lee MB, Nahum M, Vleet TMV, Rao VR, et al. An
937 Amygdala-Hippocampus Subnetwork that Encodes Variation in Human Mood.
938 *Cell* 2018;175:1688-1700.e14. <https://doi.org/10.1016/j.cell.2018.10.005>.
- 939 [47] Ashkan K, Rogers P, Bergman H, Ughratdar I. Insights into the mechanisms of
940 deep brain stimulation. *Nat Rev Neurol* 2017;13:548–54.
941 <https://doi.org/10.1038/nrneurol.2017.105>.
- 942 [48] Ramasubbu R, Lang S, Kiss ZHT. Dosing of Electrical Parameters in Deep
943 Brain Stimulation (DBS) for Intractable Depression: A Review of Clinical
944 Studies. *Front Psychiatry* 2018;9. <https://doi.org/10.3389/fpsy.2018.00302>.
- 945 [49] Okun M, Lampl I. Balance of excitation and inhibition. *Scholarpedia*
946 2009;4:7467. <https://doi.org/10.4249/scholarpedia.7467>.
- 947 [50] Hu H, Cui Y, Yang Y. Circuits and functions of the lateral habenula in health
948 and in disease. *Nat Rev Neurosci* 2020;21:277–95.
949 <https://doi.org/10.1038/s41583-020-0292-4>.
- 950 [51] Balcita-Pedicino JJ, Omelchenko N, Bell R, Sesack SR. The inhibitory
951 influence of the lateral habenula on midbrain dopamine cells: Ultrastructural
952 evidence for indirect mediation via the rostromedial mesopontine tegmental
953 nucleus. *Journal of Comparative Neurology* 2011;519:1143–64.
954 <https://doi.org/10.1002/cne.22561>.

- 955 [52] Sun Y, Cao J, Xu C, Liu X, Wang Z, Zhao H. Rostromedial tegmental nucleus-
956 substantia nigra pars compacta circuit mediates aversive and despair behavior
957 in mice. *Experimental Neurology* 2020;333:113433.
958 <https://doi.org/10.1016/j.expneurol.2020.113433>.
- 959 [53] Zhu Z, Hubbard E, Guo X, Barbosa DAN, Popal AM, Cai C, et al. A
960 connectomic analysis of deep brain stimulation for treatment-resistant
961 depression. *Brain Stimul* 2021;14:1226–33.
962 <https://doi.org/10.1016/j.brs.2021.08.010>.
- 963 [54] Yeung AWK, Wong NSM. The Historical Roots of Visual Analog Scale in
964 Psychology as Revealed by Reference Publication Year Spectroscopy. *Front*
965 *Hum Neurosci* 2019;13. <https://doi.org/10.3389/fnhum.2019.00086>.
- 966 [55] Schiratti J-B, Le Douget J-E, Le van Quyen M, Essid S, Gramfort A. An
967 ensemble learning approach to detect epileptic seizures from long intracranial
968 EEG recordings. ICASSP 2018 - 2018 IEEE International Conference on
969 Acoustics, Speech and Signal Processing (ICASSP, Calgary, Canada: IEEE;
970 2018. <https://doi.org/10.1109/ICASSP.2018.8461489>.
- 971 [56] Banville H, Wood SUN, Aimone C, Engemann D-A, Gramfort A. Robust
972 learning from corrupted EEG with dynamic spatial filtering. *NeuroImage*
973 2022;251:118994. <https://doi.org/10.1016/j.neuroimage.2022.118994>.
- 974 [57] Engemann DA, Mellot A, Höchenberger R, Banville H, Sabbagh D, Gemein L,
975 et al. A reusable benchmark of brain-age prediction from M/EEG resting-state
976 signals. *NeuroImage* 2022;262:119521.
977 <https://doi.org/10.1016/j.neuroimage.2022.119521>.
- 978 [58] Giorgino T. Computing and Visualizing Dynamic Time Warping Alignments in
979 R: The dtw Package. *J Stat Softw* 2009;31:1–24.
980 <https://doi.org/10.18637/jss.v031.i07>.
- 981 [59] Sakoe H, Chiba S. Dynamic programming algorithm optimization for spoken
982 word recognition. *IEEE Trans Acoust Speech Signal Process* 1978;26:43–9.
983 <https://doi.org/10.1109/TASSP.1978.1163055>.
- 984 [60] Veerakumar A, Tiruvadi V, Howell B, Waters AC, Crowell AL, Voytek B, et al.
985 Field potential 1/f activity in the subcallosal cingulate region as a candidate
986 signal for monitoring deep brain stimulation for treatment-resistant depression.
987 *J Neurophysiol* 2019;122:1023–35. <https://doi.org/10.1152/jn.00875.2018>.
- 988 [61] Arbutnott K, Frank J. Trail Making Test, Part B as a Measure of Executive
989 Control: Validation Using a Set-Switching Paradigm. *J Clin Exp Neuropsychol*
990 2000;22:518–28. [https://doi.org/10.1076/1380-3395\(200008\)22:4;1-0;FT518](https://doi.org/10.1076/1380-3395(200008)22:4;1-0;FT518).
- 991 [62] Salthouse TA. What Do Adult Age Differences in the Digit Symbol Substitution
992 Test Reflect? *J Gerontol* 1992;47:P121–8.
993 <https://doi.org/10.1093/geronj/47.3.P121>.
- 994 [63] Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with
995 depression. Part I: clinical characteristics. *Ann Gen Psychiatry* 2022;21:10.
996 <https://doi.org/10.1186/s12991-022-00387-1>.

- 997 [64] Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with
998 depression. Part II: relationship with functioning, well-being, and quality of life.
999 *Ann Gen Psychiatry* 2022;21:20. <https://doi.org/10.1186/s12991-022-00392-4>.
- 000 [65] Gonda X, Pompili M, Serafini G, Carvalho AF, Rihmer Z, Dome P. The role of
001 cognitive dysfunction in the symptoms and remission from depression. *Ann*
002 *Gen Psychiatry* 2015;14:27. <https://doi.org/10.1186/s12991-015-0068-9>.
- 003 [66] Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, et
004 al. Cognitive remission: a novel objective for the treatment of major depression?
005 *BMC Med* 2016;14:9. <https://doi.org/10.1186/s12916-016-0560-3>.
- 006 [67] Runia N, Mol GJJ, Hillenius T, Hassanzadeh Z, Denys D a. JP, Bergfeld IO.
007 Effects of deep brain stimulation on cognitive functioning in treatment-resistant
008 depression: a systematic review and meta-analysis. *Mol Psychiatry*
009 2023;28:4585–93. <https://doi.org/10.1038/s41380-023-02262-1>.
- 010 [68] Knowland D, Lim BK. Circuit-based frameworks of depressive behaviors: The
011 role of reward circuitry and beyond. *Pharmacol Biochem Behav* 2018;174:42–
012 52. <https://doi.org/10.1016/j.pbb.2017.12.010>.
- 013 [69] Kalin NH. The Critical Relationship Between Anxiety and Depression. *Am J*
014 *Psychiatry* 2020;177:365–7. <https://doi.org/10.1176/appi.ajp.2020.20030305>.
- 015 [70] Sampogna G, Toni C, Catapano P, Rocca BD, Di Vincenzo M, Luciano M, et
016 al. New trends in personalized treatment of depression. *Curr Opin Psychiatry*
017 2024;37:3. <https://doi.org/10.1097/YCO.0000000000000903>.
- 018 [71] Carbone A, Castelli G, Stanley HE. Time-dependent Hurst exponent in
019 financial time series. *Physica A: Statistical Mechanics and Its Applications*
020 2004;344:267–71. <https://doi.org/10.1016/j.physa.2004.06.130>.
- 021 [72] Kale M, Butar Butar F. Fractal analysis of time series and distribution
022 properties of Hurst exponent. *J Math Sci Math Educ* 2011;5:8–19.
- 023 [73] Díaz M. HA, Córdova F. On the meaning of Hurst entropy applied to EEG data
024 series. *Procedia Computer Science* 2022;199:1385–92.
025 <https://doi.org/10.1016/j.procs.2022.01.175>.
- 026 [74] Latham PE, Richmond BJ, Nelson PG, Nirenberg S. Intrinsic Dynamics in
027 Neuronal Networks. I. Theory. *Journal of Neurophysiology* 2000;83:808–27.
028 <https://doi.org/10.1152/jn.2000.83.2.808>.
- 029 [75] Pretzsch CM, Floris DL. Balancing excitation and inhibition in the autistic
030 brain. *eLife* 2020;9:e60584. <https://doi.org/10.7554/eLife.60584>.
- 031 [76] Trakoshis S, Martínez-Cañada P, Rocchi F, Canella C, You W, Chakrabarti B,
032 et al. Intrinsic excitation-inhibition imbalance affects medial prefrontal cortex
033 differently in autistic men versus women. *eLife* 2020;9:e55684.
034 <https://doi.org/10.7554/eLife.55684>.
- 035 [77] Porjesz B, Almasy L, Edenberg HJ, Wang K, Chorlian DB, Foroud T, et al.
036 Linkage disequilibrium between the beta frequency of the human EEG and a
037 GABAA receptor gene locus. *Proceedings of the National Academy of*
038 *Sciences* 2002;99:3729–33. <https://doi.org/10.1073/pnas.052716399>.

- 039 [78] Turrigiano GG, Nelson SB. Homeostatic plasticity in the developing nervous
040 system. *Nat Rev Neurosci* 2004;5:97–107. <https://doi.org/10.1038/nrn1327>.
- 041 [79] Atallah BV, Scanziani M. Instantaneous Modulation of Gamma Oscillation
042 Frequency by Balancing Excitation with Inhibition. *Neuron* 2009;62:566–77.
043 <https://doi.org/10.1016/j.neuron.2009.04.027>.
- 044 [80] Gao R, Peterson EJ, Voytek B. Inferring synaptic excitation/inhibition balance
045 from field potentials. *NeuroImage* 2017;158:70–8.
046 <https://doi.org/10.1016/j.neuroimage.2017.06.078>.
- 047 [81] Daume J, Kamiński J, Schjetnan AGP, Salimpour Y, Khan U, Kyzar M, et al.
048 Control of working memory by phase–amplitude coupling of human
049 hippocampal neurons. *Nature* 2024;629:393–401.
050 <https://doi.org/10.1038/s41586-024-07309-z>.
- 051 [82] Liu Y, Postupna N, Falkenberg J, Anderson ME. High frequency deep brain
052 stimulation: What are the therapeutic mechanisms? *Neurosci Biobehav Rev*
053 2008;32:343–51. <https://doi.org/10.1016/j.neubiorev.2006.10.007>.
- 054 [83] Sani S, Busnello J, Kochanski R, Cohen Y, Gibbons RD. High-frequency
055 measurement of depressive severity in a patient treated for severe treatment-
056 resistant depression with deep-brain stimulation. *Transl Psychiatry*
057 2017;7:e1207–e1207. <https://doi.org/10.1038/tp.2017.145>.
- 058 [84] McIntyre CC, Anderson RW. Deep brain stimulation mechanisms: the control
059 of network activity via neurochemistry modulation. *J Neurochem*
060 2016;139:338–45. <https://doi.org/10.1111/jnc.13649>.
- 061 [85] Iturrate I, Pereira M, Millán J del R. Closed-loop electrical neurostimulation:
062 Challenges and opportunities. *Curr Opin Biomed Eng* 2018;8:28–37.
063 <https://doi.org/10.1016/j.cobme.2018.09.007>.
- 064